

## Original

# Cell activation state influences the modulation of HLA-DR surface expression on human monocytes/macrophages by parenteral fish oil lipid emulsion

R. S. Torrinhas, T. Jacintho, H. Goto, M. Gidlund, M. M. Sales, P. A. Oliveira and D. L. Waitzberg

University of São Paulo Medical School. São Paulo (SP). Brazil.

### Abstract

Abnormal surface expression of HLA-DR by leukocytes is associated with a poor prognosis in critical care patients. Critical care patients often receive total parenteral nutrition with lipid emulsion (LE). In this study we evaluated the influence of fish oil LE (FO) on human monocyte/macrophage (M $\phi$ ) expression of surface HLA-DR under distinct activation states. Mononuclear leukocytes from the peripheral blood of healthy volunteers (n=18) were cultured for 24 hours without LE (control) or with 3 different concentrations (0.1, 0.25, and 0.5%) of the follow LE: a) pure FO b) FO in association (1:1-v/v) with LE composed of 50% medium-chain trygliceride and 50% soybean oil (MCTSO), and c) pure MCTSO. The leukocytes were also submitted to different cell activation states, as determinate by INF- $\gamma$  addition time: no INF- $\gamma$  addition, 18 hours before, or at the time of LE addition. HLA-DR expression on M $\phi$  surface was evaluated by flow cytometry using specific monoclonal antibodies. In relation to controls (for 0.1%, 0.25%, and 0.5%: 100) FO decreased the expression of HLA-DR when added alone [in simultaneously-activated M $\phi$ , for 0.1%: 70 (59  $\pm$  73); for 0.25%: 51 (48  $\pm$  56); and for 0.5%: 52.5 (50  $\pm$  58)] or in association with MCTSO [in simultaneously-activated M $\phi$ , for 0.1%: 50.5 (47  $\pm$  61); for 25%: 49 (45  $\pm$  52); and for 0.5%: 51 (44  $\pm$  54) and in previously-activated Mf, for 1.0%: 63 (44  $\pm$  88); for 0.25%: 70 (41  $\pm$  88); and for 0.5%: 59.5 (39  $\pm$  79)] in culture medium (Friedman p < 0.05). In relation to controls (for 0.1%, 0.25%, and 0.5%: 100), FO did not influence the expression of these molecules on non-activated M $\phi$  [for 0.1%: 87.5 (75 $\pm$ 93); for 0.25%: 111 (98  $\pm$  118); and for 0.5%: 101.5 (84  $\pm$  113)]. Results show that parenteral FO modulates the expression of HLA-DR on human M $\phi$  surface accordingly to leukocyte activation state. Further clinical

### EL ESTADO DE ACTIVACIÓN CELULAR INFLUYE EN LA MODULACIÓN DE LA EXPRESIÓN DEL HLA-DR SOBRE LA SUPERFICIE DE MONOCITOS/MACRÓFAGOS HUMANOS POR UNA EMULSIÓN LIPÍDICA PARENTERAL DE ACEITE DE PESCADO

### Resumen

La expresión anómala del HLA-DR sobre la superficie de los leucocitos se asocia con un pronóstico sombrío en pacientes críticos. A menudo, estos pacientes reciben nutrición parenteral total con una emulsión lipídica (EL). En este estudio, evaluamos la influencia de una EL de aceite de pescado (AP) en la expresión del HLA-DR en la superficie de monocitos/macrófagos humanos (M $\phi$ ) bajo diferentes estados de activación. Se cultivaron leucocitos mononucleares de sangre periférica de voluntarios sanos (n = 18) durante 24 horas sin la EL (control) o con 3 concentraciones distintas (0,1, 0,25 y 0,5%) de la siguiente EL: a) AP puro b) AP en asociación con EL (1:1 v/v) compuesta de 50% de triglicéridos de cadena media y 50% de aceite de soja (TCMAS), y c) TCMAS puro. También sometimos a los leucocitos a diferentes estados de activación celular, determinado por INF- $\gamma$  tiempo de adición: no INF- $\gamma$  adición 18 horas antes, o en el momento de añadir la EL. La expresión del HLA-DR sobre la superficie de los M $\phi$  se evaluó mediante citometría de flujo utilizando anticuerpos monoclonales específicos. En relación con los controles (para 0,1%, 0,25% y 0,5%: 100) el AP disminuyó la expresión de HLA-DR cuando se añadía solo [en M $\phi$  activados simultáneamente, para 0,1%: 70 (59  $\pm$  73); para 0,25%: 51 (48  $\pm$  56); y para 0,5%: 52,5 (50  $\pm$  58)] o en asociación con TCMAS [en M $\phi$  activados simultáneamente para 0,1%: 50,5 (47  $\pm$  61); para 0,25%: 49 (45  $\pm$  52); y para 0,5%: 51 (44  $\pm$  54) y en M $\phi$  previamente activados para 0,1%: 63 (44  $\pm$  88); para 0,25%: 70 (41  $\pm$  88); y para 0,5%: 59,5 (39  $\pm$  79)] en el medio de cultivo (Friedman p < 0,05). Con respecto a los controles, (para 0,1%, 0,25% y 0,5%: 100), el AP no influyó en la expresión de estas moléculas en M $\phi$  no activados [para 0,1%: 87,5 (75  $\pm$  93); para 0,25%: 111 (98  $\pm$  118); y para 0,5%: 101,5 (84  $\pm$  113)]. Los resultados muestran que el AP parenteral modula la expresión del HLA-DR sobre la superficie de los M $\phi$  humanos en función del estado de activación leucocitaria. Estudios clínicos adicionales que

**Correspondence:** Raquel Susana Matos de Miranda Torrinhas.  
Av. Dr Arnaldo 455, 2ª andar - sala 2208.  
CEP 01246-903 Cerqueira César, São Paulo (SP)-Brazil.  
E-mail: metanutri@usp.br

Recibido: 4-I-2010.  
Aceptado: 3-V-2010.

studies evaluating the ideal moment of fish oil LE infusion to modulate leukocyte functions may contribute to a better understanding of its immune modulatory properties.

(*Nutr Hosp.* 2011;26:311-316)

DOI:10.3305/nh.2011.26.2.4648

Key words: *Parenteral fata emulsions. HLA-DR. Fish oil.*

## Introduction

Critical care patients receiving parenteral nutrition may undergo changes in inflammatory and immune function. Fatty acids (FA) from parenteral lipid emulsions (LE) can be incorporated into leukocyte membranes and, according to their physical chemistry characteristics, may influence cellular immunological functions. In this sense, LE infusion may attenuate or amplify inflammation and immune function with impact on clinical outcome, according to their FA content.<sup>1-3</sup> Eicosapentaenoic (EPA) and docosahexaenoic (DHA) FA present in fish oil LE (FO) have been shown to improve leukocyte function and exert anti-inflammatory effects in experimental models and clinical trials.<sup>4-10</sup>

Monocytes/macrophages actively participate in the innate and acquired immune responses against foreign antigens. Human leukocyte antigen (HLA) molecules from the major complex of histocompatibility class II (MHC II) system expressed on monocytes/macrophages surface represent the link between innate and acquired immunity, playing a central role in activation of the cell-mediated immune response.<sup>11</sup>

Abnormal expression of HLA-DR is associated with a poor prognosis in several clinical conditions. For instance, increased surface expression of HLA-DR in activated monocytes/macrophages is seen in patients with rheumatoid arthritis and is associated with stronger activation of their inflammatory response and worsening of their clinical condition.<sup>12</sup> On the other hand, a marked decrease of surface HLA-DR in monocytes can be observed after massive hyper-inflammatory reactions and is associated with functional deactivation of monocytes and poor prognosis in sepsis.<sup>13,14</sup>

Taken together, these observations suggest that surface expression of HLA-DR on monocytes/macrophages is strongly dependent on the activation state of these leukocytes. Increment or decrement of such expression may be desirable, according to the patient's clinical condition.

The use of FO has been proposed in critical care patients in attempt to attenuate inflammation. It has been demonstrated clinically that the FO infusion in these patients is associated with decreased production of inflammatory cytokines.<sup>9-10</sup> From a mechanistic point of view, it is of interest to study the modification of a central immune signaling molecule under different stress states via the use of FO.

evalúen el momento idóneo de añadir la infusión de EL con aceite de pescado para modular las funciones leucocitarias podrían contribuir a entender mejor sus propiedades inmunomoduladoras.

(*Nutr Hosp.* 2011;26:311-316)

DOI:10.3305/nh.2011.26.2.4648

Palabras clave: *Emulsión lipídica parenteral. HLA-DR. Aceite de pescado.*

The aim of the present study was to evaluate the effect of FO on surface expression of HLA-DR by human monocyte/macrophage at different activations states.

## Methods

### Subjects

After local ethical committee (Comissão de Ética para Análise de Projetos de Pesquisa-CAPPesq) approval, heparinized blood samples were drawn from healthy adult (20-40 year old) male volunteers (n = 18) selected by a questionnaire. The questionnaire excluded smokers, athletes, alcoholic, drugs users, and illness up 3 weeks prior to blood collection.

### Obtaining mononuclear leukocytes

Mononuclear leukocytes were isolated from whole blood by Ficoll-Hypaque (Histopaque® 1077, Sigma-Aldrich-USA) density gradient centrifugation, according to the modified Boyum technique.<sup>15</sup> Briefly, peripheral blood from each donor (usually 40mL) was collected into heparinized vacuum tubes (Vacutainer®, Becton-Dickinson - USA), diluted (1:1) in saline (Baxter-USA), added to 50 mL tubes (BD Falcon™-USA) containing Ficoll-Hypaque (2:1) and centrifuged (Eppendorf 5810R-USA) for 30 minutes at 2,000 rpm and 18°C. Mononuclear cells at the interface were aspirated and washed twice with equal volume of phosphate buffered saline (PBS) pH 7.2 (Sigma-USA), to be further cultured with different LE.

### Mononuclear leukocyte culture with LE

After mononuclear leukocyte separation, the cells were plated under sterile conditions in 24 wells plates (Costar-USA),  $2 \times 10^6$  cells per well, and cultured with or without  $4 \times 10^5$  U/L of INF- $\gamma$  (Genzyme-USA). According to the moment of INF- $\gamma$  addition to the culture, mononuclear leukocytes were considered to have 3 different activation states: non-activated: without INF- $\gamma$  addition; previously-activated: with INF- $\gamma$  addition 18 hours before LE addition; and simultaneously-

activated: with INF- $\gamma$  addition at the same time of LE. LE were added at 0.1%, 0.25%, and 0.5% concentrations in 1 mL of HEPES buffer RPMI medium (RPMI 1640, Gibco-USA), with 2 mL of EL in 2 mL of medium containing 5% heat-inactivated fetal calf serum (Gibco-USA),  $1 \times 10^5$  U/L penicillin (Sigma - USA), and 0.07 mmol/L gentamicin (Sigma-USA). Cells remained in culture 24 hours.

According to the type of LE added in non-activated, previously activated or simultaneously activated mononuclear leukocytes, there were 7 experimental groups: C-control without LE; MCT-LE composed of a physical mixture of 50% medium chain triglycerides and 50% soybean oil (Lipovenos<sup>®</sup> MCT 20%, Fresenius-Kabi-Germany); FO-fish oil LE (Omegavenos<sup>®</sup> 10%, Fresenius-Kabi-Germany); and MCTFO-LE composed of an experimental mixture of the LE composed by a physical mixture of medium chain triglycerides and soybean oil with FO (1:1 v/v). Table I describes the usual compositions of all LE.

During the entire culture period, mononuclear leukocytes were kept in a moist atmosphere at 37°C in a 4% CO<sub>2</sub> incubator (Revco Elite, Revco Technologies-USA). The mononuclear leukocytes were found to be > 90% viable, as assessed by Trypan Blue (Sigma-USA) exclusion.

**Table I**  
Fatty acid composition of studied parenteral lipid emulsions

Fatty	Lipovenoes MCT 20% <sup>o*</sup>	Omegaven 10% <sup>o†</sup>
Caproic	0.3	–
Caprylic	60.0	–
Capric	33.8	–
Lauric	0.4	–
Myristic	0.1	4.7
Palmitic	13.0	10.6
Palmitoleic	0.3	8.6
Stearic	5.2	2.1
Oleic	24.9	14.3
Linoleic	52.4	3.3
Stearidonic	–	3.8
Arachidonic	–	2.6
Alpha-Linolenic	7.5	1.2
Eicosapentaenoic	–	20.6
Docosapentaenoic	–	2.4
Docosahexaenoic	–	15.8

Data supplied by the manufacturers of the lipid emulsions (Fresenius Kabi and Baxter).

\*Values expressed in g/L for 20% lipid emulsions (oil = 200 g/L, egg phosphatide = 12 g/L, glycerol = 25 g/L, and  $\alpha$ -tocopherol = 0.1 g/L).

†Omegaven is available as lipid emulsion supplement only and has to be added to a standard lipid emulsion. Values expressed in g/L for 10% lipid emulsions (oil = 100 g/L, egg phosphatide = 12 g/L, glycerol = 25 g/L, and  $\alpha$ -tocopherol = 0.2 g/L).

### Immunofluorescence staining and flow cytometry analysis

After LE culture, the leukocytes were washed twice with PBS and incubated in a dark room at 4°C for 30 minutes with 10 mL of AB serum and 10mL of the following monoclonal antibodies: anti-HLA-DR stained with phycoerythrin (PE) and anti-CD14 stained with allophycocyanin (APC), all from BD Pharmigen- USA. Nonspecific binding was corrected by using cells stained with the appropriate isotype-matched immunoglobulin (Ig) controls (BD Pharmigen-USA). After incubation, mononuclear leukocytes were washed twice with 2 mL of PBS and fixed with 250mL of 1% paraformaldehyde (Sigma-USA) solution immediately before flow cytometry acquisition.

### Flow cytometry analysis

Analysis of HLA-DR expression was performed using a FACSCalibur flow cytometer (Becton & Dickinson-USA) calibrated daily with fluorescent 1-mm latex beads (Calibrate<sup>™</sup> 3, Becton & Dickson-USA) and CellQuest<sup>™</sup> 3 software (Becton & Dickinson-USA). A 488 nm laser line was used to simultaneously excite the fluorochromes FITC, PE, Cy-Chromo, and APC staining the monoclonal antibodies. Forward angle and 90° light scatter characteristics were also recorded for each cell in order to distinguish different leukocytes according to size and internal complexity. Monocytes/macrophages were identified on this basis and by gating on a side versus CD14 dot plot. The expression of HLA-DR was evaluated as means of fluorescence intensity (10,000 events per sample) and nonspecific binding was corrected by excluding the mean values of fluorescence intensity from isotype-matched Ig controls.

### Statistical analysis

The mean of data from fluorescence intensity samples was converted to percentage of the basal expression determined by the control group (considered as 100%). Friedman test followed by the Student-Newman-Keuls post hoc test were applied to compare differences across groups using SigmaStat software (Sigma-EUA).  $P \leq 0.05$  was considered statistically significant.

## Results

FO did not influence surface expression of HLA-DR on non-activated monocytes/macrophages. In the MCT group, all studied lipid emulsions concentrations decreased HLA-DR expression on non-activated monocytes/macrophages ( $P = 0.0042$ , table II).

For previously-activated monocytes/macrophages, FO combined with LE rich in medium-chain triglyc-

**Table II**  
Expression of HLA-DR on the surface of human monocyte/macrophage under different activation state cultured with different lipid emulsions

Mφ state	FO 0.10%	FO 0.25%	FO 0.50%	MCT 0.10%	MCT 0.25%	MCT 0.50%	MCTFO 0.10%	MCTFO 0.25%	MCTFO 0.50%
NA	87.5 (75 ± 93)	111 (98 ± 118)	101.5 (84 ± 113)	82 <sup>y</sup> (76 ± 88)	118 (111 ± 134)	104.5 (102 ± 122)	85 (77 ± 103)	109.5 (85 ± 117)	90.5 (86 ± 96)
PA	91 (48 ± 110)	78 (46 ± 95)	77.5 (57 ± 102)	99.5 (78 ± 118)	98 (88 ± 108)	87 (77 ± 95)	63* (44 ± 88)	70* (41 ± 88)	59.5* (39 ± 79)
SA	70* (59 ± 73)	51* (48 ± 56)	52.5* (50 ± 58)	94 (80 ± 102)	92.5 (81 ± 106)	98.5 (83 ± 108)	50.5 <sup>s</sup> (47 ± 61)	49* (45 ± 52)	51* (44 ± 54)

Legend - Mφ: monocytes/macrophages; FO: fish oil lipid emulsion; MCT: lipid emulsion rich in medium chain triglycerides; MCTFO: lipid emulsion composed by a physical mixture of FO with MCT (1:1); PA: previously-activated; ST: simultaneously-activated; NA: non-activated.

For the same state of activation ( $p < 0.05$ ):

\*versus control without lipid emulsion (100).

<sup>y</sup>versus control without lipid emulsion (100); versus FO 0.10%; and versus MCT in the same concentration.

<sup>s</sup>versus control without lipid emulsion (100); versus FO 0.10%; and versus MCT 0.10%.

<sup>v</sup>versus control without lipid emulsion (100); versus MCT 0.25%; and versus MCT 0.50%.

erides at all concentrations decreased expression of HLA-DR compared to controls without LE ( $P = 0.019$ , table II).

For simultaneously-activated monocytes/macrophages, FO alone at all concentrations with significant doses dependence ( $P = 0.004$ , table II) and also when associated with LE rich in medium-chain triglycerides at all concentrations ( $P = 0.007$ , table II) decreased HLA-DR expression compared to control. This inhibitory effect was highest in the MCTFO group with an LE concentration of 0.10% ( $P = 0.006$ , table II). Both 0.25% ( $P = 0.0003$ ) and 0.50% ( $P < 0.0001$ ) concentrations of FO alone or combined with LE rich in medium-chain triglycerides decreased the expression of HLA-DR (table II).

## Discussion

In order to simulate the environment of the blood stream during parenteral infusion of lipid emulsions, our *in vitro* experimental model was designed considering the culture of total mononuclear cells instead of just monocytes/macrophages, because leukocyte interactions that occur in *in vivo* may influence their response to external stimuli.<sup>16</sup>

The reported physiological concentration of LE in leukocyte cultures varies widely. In order to determine the ideal concentration of LE for our experimental model, we conducted a pilot study and tested cell viability using trypan blue dye exclusion in monocytes/macrophages cultures ranging 0.1-1% of lipid emulsion in culture medium. Cultures with 1% FO in both previously and simultaneously activated monocytes/macrophages were associated with less than 80% cell viability, probably due to excessive production of free radicals associated with polyunsaturated FA combined with those provided by leukocyte reaction after INF-

gamma stimuli.<sup>17,18</sup> Thus the 1% concentration of FO was excluded.

We compared the effect of pure FO on HLA-DR versus LE composed of 50% medium chain triglyceride and 50% soybean oil (MCT/LCT) because the latter is largely used in clinical practice and is associated with few effects on immune function.<sup>19,20</sup> Considering that FO is infused in combination with other conventional LE (soybean oil LE, MCT/LCT, or LE composed of 80% olive oil and 20% soybean oil) in clinical practice, we also compared the effect of pure FO with a experimental mixture composed of a high concentration of this LE with MCT/LCT (1:1).<sup>19</sup>

INF- $\gamma$  was chosen as an external stimuli to activate human monocytes/macrophages because this cytokine up-regulates the surface expression of HLA-DR molecules on mononuclear leukocytes.<sup>21</sup>

Our results show that FO influences HLA-DR surface expression by monocytes/macrophages according to the leukocyte activation state. FO alone and mainly when combined at high doses with MCTSO (1:1) decreased surface expression of HLA-DR on simultaneously or previously-activated monocytes/macrophages but had no effect on leukocytes that were not activated.

Despite methodological differences, the improved effects observed with the mixture of FO and MCTSO versus pure FO were also observed in our previous studies. These studies showed the FO-MCTSO combination to increase the favorable effect of FO on eicosanoid production in a experimental model of colitis and also to favorably effect the number of spleen resident, non-opsonized carbon particle phagocytosing-macrophages in rats.<sup>22,4</sup> The stronger effect of the FO-MCTSO mixture when compared to pure FO may be related to improved use of omega-3 FA by monocytes/macrophages. While omega-3 FA from FO are poor substrates for lipoprotein lipase (LPL), parenteral medium chain triglycerides (MCT) are more quickly degraded by this enzyme and

are also a quick source of energy. Experimental studies showed that when omega-3 FA are infused with MCT, they are more easily released for cellular use.<sup>23</sup>

In fact, our findings may be a result of the fatty acids EPA and DHA, which are provided by FO. In another experimental study, the *in vitro* effect of EPA and DHA on HLA-DR expression was evaluated in non-activated monocytes/macrophages and INF- $\gamma$ -activated human monocytes/macrophages, where INF- $\gamma$  stimulation occurred at the same time as EPA and DHA addition, corresponding to the simultaneously activated group of our study.<sup>24</sup> In agreement with our findings, EPA and DHA did not change HLA-DR expression on human non-activated monocytes but decreased the expression of these molecules on INF- $\gamma$  activated monocytes and also decreased their ability to present antigen to autologous lymphocytes.<sup>24</sup>

A reduction in antigen-presenting function may impair T cell activation, thus decreasing both inflammatory cytokine and  $\beta$  cell production. It was shown that cell activation state can influence the immunomodulatory effect of fish oil on cytokine production.<sup>25</sup> Mice fed fish oil for 6 weeks showed decreased *ex vivo* production of TNF- $\alpha$  and IL-1 $\beta$  by inflammatory macrophages (induced by intraperitoneal injection of thioglycollate broth 4 d prior to sacrifice) but not by non-inflammatory resident macrophages, which increased TNF- $\alpha$  production.<sup>25</sup> Despite methodological discrepancies, these findings are in agreement with the present study in demonstrating the inhibitory effect of fish oil on immune variables only under a cell activation stimulus. In addition, our data may also corroborate to suggest a possible reduction of antigen-presenting function through HLA-DR inhibition by fish oil as a possible mechanism related to the observed decrease in inflammatory cytokine production.

Despite methodological differences, our findings are also in accordance with other experimental studies that found an inhibition of Ia molecules (the mice equivalent of HLA-DR molecules) by fish oil. In mice genetically modified to develop autoimmune lupus (MRL-lpr mice) the ingestion of fish oil was associated with disease suppression and decreased Ia expression.<sup>26</sup> Mice and rats fed fish oil via esophageal gavage showed a reduced percentage of peritoneal macrophages expressing Ia.<sup>27</sup> *Listeria monocytogenes*-infected mice fed with fish oil had decreased expression of Ia on the surface of peritoneal macrophages in relation to mice fed with other fat sources.<sup>28</sup> Similar to our observation of HLA-DR inhibition by FO in monocytes/macrophages under a stress stimulus, these other reports also had a stress factor present (disease, esophageal gavages, and induced infection) during or before the fish oil supply.

The recognized anti-inflammatory properties of omega-3 fatty acids provided by fish oil have been speculated to be useful in treating chronic and hyperinflammatory conditions.<sup>29</sup> Simultaneously activated monocytes/macrophages may be considered a valid *in vitro* model to simulate chronic inflammation, where leukocytes are under frequent activation stimuli. Con-

sidering that in chronic inflammatory conditions, such as rheumatoid arthritis and atherosclerosis, increased HLA-DR expression on macrophages surface may be present and associated with disease severity,<sup>30,31</sup> it is possible that reduced expression of these surface molecules induced by FO on simultaneously activated monocytes/macrophages could be protective against chronic inflammation, but further studies are required to confirm this hypothesis.

In addition, the decreased expression of HLA-DR on simultaneously or previously activated but not on non-activated human monocytes/macrophages after FO culture suggests a potential benefit in the use this LE in hyperinflammatory conditions followed by an immunodeficiency state, as occurs in sepsis, severe trauma, and burns.<sup>14</sup> Our experimental data suggest that FO could prevent excessive monocytes/macrophages activation without the impairment of functional surface molecule expression. The clinical application of these experimental data remains to be further elucidated.

There are several mechanisms potentially involved in the modulatory effect of FO on HLA-DR surface expression by simultaneously or previously activated monocytes/macrophages. They include incorporation of omega-3 polyunsaturated fatty acids into the cell membrane, modification of lipid rafts, modulation of eicosanoids production, and modulation of gene expression for inflammatory mediators or surface molecules.<sup>32-37</sup> While each of these proposed mechanisms has support in the scientific literature, they were not evaluated in the present study and require further analysis.

Taken together, our findings allow us to suggest that leukocyte activation state may be responsible for the overall disparate data regarding the *in vitro* effects of FO on immune function. Previously, these discrepancies have been attributed mainly to methodological variables between the scientific reports, such as differences in the cell culture conditions.

Regarding the substantial limitations to extrapolation of experimental *in vitro* results to clinical application, our findings also suggest that the patient's clinical condition may be crucial in determining the immune modulatory effect of FO.

## Conclusion

Fish oil lipid emulsion, mainly when associated with lipid emulsion rich in medium-chain triglycerides, distinctly influences surface expression of HLA-DR on activated monocyte/macrophages. The inhibition of HLA-DR by FO may be protective in conditions where monocytes/macrophages are in constant activation.

## Acknowledgments

The authors thank Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP- 98/11379-9 and

99/08332-3) for financial support and Fresenius Kabi for kindly providing the parenteral lipid emulsions.

## References

1. Calder PC. Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients. *Braz J Med Biol Res* 2003; 36: 433-446.
2. Kinsella JE. Lipids, membrane receptors, and enzymes: effects of dietary fatty acids. *JPEN J Parenter Enteral Nutr* 1990; 14 (Suppl. 5): S200-S217.
3. Senkal M, Geier B, Hannemann M, Deska T, Linseisen J, Wolfram G, Adolph M. Supplementation of  $\omega$ -3 Fatty Acids in Parenteral Nutrition Beneficially Alters Phospholipid Fatty Acid Pattern *Journal of Parenteral and Enteral Nutrition*. 2007; 31: 12-17.
4. Nardi L De, Bellinati-Pires R, Torrinhas RS., Bacchi CE., Arias V and Waitzberg DL. Effect of fish oil containing parenteral lipid emulsions on neutrophil chemotaxis and resident-macrophages' phagocytosis in rats. *Clinical Nutrition* 2008; 27: 283-288.
5. Jacintho TM, Marques CG, Torrinhas RS, Sales MM, Goto H, Giglund M, Gama-Rodrigues J, Waitzberg DL. Efeitos de diferentes emulsões lipídicas sobre a expressão de moléculas de superfície envolvidas no processo de apresentação de antígenos em células mononucleares humanas in vitro. *ABCD. Arquivos Brasileiros de Cirurgia Digestiva, Brasil* 2005; 18: 13-18.
6. Morlion BJ, Torwesten E, Lessire H, et al. The effect of parenteral fish oil on leukocyte membrane fatty acid composition and leukotriene-synthesizing capacity in patients with postoperative trauma. *Metabolism* 1996; 45: 1208-1213.
7. Schauder P, Rohn U, Schafer G, et al. Impact of fish oil enriched total parenteral nutrition on DNA synthesis, cytokine release and receptor expression by lymphocytes in the postoperative period. *Br J Nutr* 2002; 87 (Suppl. 1): S103-S110.
8. Weiss G, Meyer F, Matthies B, Pross M, Koenig W, Lippert H. Immunomodulation by perioperative administration of n-3 fatty acids. *Br J Nutr* 2002; 87 (Suppl. 1): S89-S94.
9. Mayer K, Gokorsch S, Fegbeutel C, et al. Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis. *Am J Respir Crit Care Med* 2003; 167: 1321-1328.
10. Mayer K, Fegbeutel C, Hattar K, et al. Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. *Intensive Care Med* 2003; 29: 1472-1481.
11. Bach, F. H Class II genes and products of the HLA-D region. *Immunol Today* 1985; 6: 89-94.
12. Thomas R. Antigen-presenting cells in rheumatoid arthritis. *Springer Semin Immunopathol* 1998; 20: 53-72.
13. Spittler A, Roth E. Is monocyte HLA-DR expression predictive for clinical outcome in sepsis? *Intensive Care Med* 2003; 29: 1211-2.
14. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Müller JM, Döcke WD, Kox WJ. Monocyte deactivation—rationale for a new therapeutic strategy in sepsis. *Intensive Care Med* 1996; 22: S474-81.
15. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. *Scand J Clin Lab Invest* 1968; 21: 77-89.
16. Cline MJ, Swett VC. The interaction of human monocytes and lymphocytes. *J Exp Med* 1968; 128: 1309-25.
17. Das U. A radical approach to cancer. *Med Sci Monit* 2002; (4): RA79-92.
18. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med* 1999; 340: 115-26.
19. Waitzberg DL, Torrinhas RS, Jacintho TM. New Parenteral Lipid Emulsions for Clinical Use *J Parent Enteral Nutr* 2006; 30: 351-367.
20. Wanten GJA, Calder PC. Immune modulation by parenteral lipid emulsions *Am J Clin Nutr* 2007; 85: 1171-1184.
21. Basham TY, Merigan TC. Recombinant interferon-gamma increases HLA-DR synthesis and expression. *J Immunol* 1983; 130: 1492-4.
22. Campos FG, Waitzberg DL, Habr-Gama A, Logullo AF, Noronha IL, Jancar S, Torrinhas RS, Fürst P. Impact of parenteral n-3 fatty acids on experimental acute colitis. *Br J Nutr* 2002; 87 (Suppl. 1): S83-8.
23. Carpentier YA, Hacquebard M. Intravenous lipid emulsions to deliver omega 3 fatty acids. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 2006; 75: 145-148.
24. Hughes DA, Pinder AC. N-3 polyunsaturated fatty acids modulate the expression of functionally associated molecules on human monocytes and inhibit antigen-presentation in vitro. *Clin Exp Immunol* 1997; 110: 516-23.
25. Wallace FA, Miles EA, Calder PC. Activation state alters the effect of dietary fatty acids on pro-inflammatory mediator production by murine macrophages. *Cytokine* 2000; 12: 1374-9.
26. Kelley VE, Ferretti A, Izui S, Strom TB. A fish oil diet rich in eicosapentaenoic acid reduces cyclooxygenase metabolites, and suppresses lupus in MRL-lpr mice. *J Immunol* 1985; 134: 1914-9.
27. Mosquera J, Rodríguez-Iturbe B, Parra G. Fish oil dietary supplementation reduces Ia expression in rat and mouse peritoneal macrophages. *Clin Immunol Immunopathol* 1990; 56: 124-9.
28. Huang S, Misfeldt M, Pritsche K. Dietary Fat Influences Ia Antigen Expression and Immune Cell Populations in the Murine Peritoneum and Spleen. *J Nutr* 1992; 122: 1219-1231.
29. Fürst P, Kuhn KS. Fish oil emulsions: what benefit can they bring? *Clin Nutr* 2000; 19: 7-14.
30. Firestein GS, Zvaifler NJ. Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. I. A cytofluorographic study of monocyte differentiation antigens and class II antigens and their regulation by gamma-interferon. *Arthritis Rheum* 1987; 30: 857-863.
31. Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature (Lond)* 1993; 362: 801-809.
32. Muller CP, Stephany DA, Shinitzky M, Wunderlich JR. Changes in cell-surface expression of MHC and Thy-1.2 determinants following treatment with lipid modulating agents. *J Immunol* 1983; 131: 1356-1362.
33. Siddiqui RA, Harvey KA, Zaloga GP, Stillwell W. Modulation of Lipid Rafts by n-3 Fatty Acids in Inflammation and Cancer: Implications for Use of Lipids During Nutrition Support. *Nutr Clin Practice* 2007; 22: 74-88.
34. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr, Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. *Arterioscler Thromb* 1994; 14: 1829-36.
35. De Caterina R, Madonna R, Massaro M. Effects of omega-3 fatty acids on cytokines and adhesion molecules. *Curr Atheroscler Rep* 2004; 6: 485-91.
36. Wanten GJA, Calder PC. Immune modulation by parenteral lipid emulsions *Am J Clin Nutr* 2007; 85: 1171-84.
37. Deckelbaum RJ, Worgall TS, Seo T. n-3 Fatty acids and gene expression. *Am J Clin Nutr* 2006; 83 (Suppl.): S1520-5.